Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project

Christopher J. Ricketts¹, Victoria K. Hill², W. Marston Linehan¹*

¹ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, ² Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America

Abstract

The recent publication of the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project has provided an immense wealth and breadth of data providing an invaluable tool for confirmation and expansion upon previous observations in a large data set containing multiple data types including DNA methylation, somatic mutation, and clinical information. In clear cell renal cell carcinoma (CCRCC) many genes have been demonstrated to be epigenetically inactivated by promoter hypermethylated and in a small number of cases to be associated with clinical outcome. This study created two cohorts based on the Illumina BeadChip array used to confirm the frequency of tumor-specific hypermethylation of these published hypermethylated genes, assess the impact of somatic mutation or chromosomal loss and provide the most comprehensive assessment to date of the association of this hypermethylation with patient survival. Hypermethylation of the Fibrillin 2 (FBN2) gene was the most consistent epigenetic biomarker for CCRCC across both cohorts in 40.2% or 52.5% of tumors respectively. Hypermethylation of the secreted frizzled-related protein 1 (SFRP1) gene and the basonuclin 1 (BNC1) gene were both statistically associated with poorer survival in both cohorts (SFRP1 - p ⩽ 0.0001 or 0.0010 and BNC1 - p ⩽ 0.0001 or 0.0380) and represented better independent markers of survival than tumor stage, grade or dimension in one cohort and tumor stage or dimension in the other cohort. Loss of the SFRP1 protein can potentially activate the WNT pathway and this analysis highlighted hypermethylation of several other WNT pathway regulating genes and demonstrated a poorer survival outcome for patients with somatic mutation of these genes. The success of demethylating drugs in hematological malignancies and the current trials in solid tumors suggest that the identification of clinically relevant hypermethylated genes combined with therapeutic advances may improve the effectiveness and usefulness of such drugs in clear cell renal cell carcinoma.

Citation: Ricketts CJ, Hill VK, Linehan WM (2014) Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. PLoS ONE 9(1): e85621. doi:10.1371/journal.pone.0085621

Editor: Mohammad O. Hoque, Johns Hopkins University, United States of America

Received August 12, 2013; Accepted December 5, 2013; Published January 15, 2014

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: WML@nih.gov

Introduction

Renal cell carcinoma (RCC) is diagnosed in >200,000 individuals in the world each year, accounting for ~2% of all cancers [1]. In the U.S. it is estimated that in 2013 65,150 individuals (40,430 men and 24,720 women) will be diagnosed with this chemotherapy-resistant disease and that 13,630 individuals (40,430 men and 24,720 women) will be diagnosed with this chemotherapy-resistant disease and that 13,630 individ-

The report demonstrated that tumor promoter hypermethylation was increased compared to normal kidney and increased in association with both higher stage and grade as well as demonstrating a specific hypomethylation profile in association with mutation of the SETD2 mutation [6]. Additionally, the methylation profiles within the tumors could be used to subset the RCC patients and this differentiated for their overall survival [6]. That aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs), may play an important role in the development of renal cell carcinoma has been known for some time [11]. In CCRCC it has been shown that the VHL tumor suppressor gene is inactivated by promoter hypermethylation in ~15% of cases [5,12,13] and that other tumor suppressor genes, such as RASSF1, can be commonly hypermethylated while they are rarely mutated [14,15]. Additional to these examples there are reports of greater than 60 candidate tumor suppressor genes that demonstrate
Methods

Ethics Statement

All patient data was acquired from the published TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project [6] and within this publication it is stated “Specimens were obtained from patients, with appropriate consent from institutional review boards”. This data can be accessed by going to the online open access Nature article entitled “Comprehensive molecular characterization of clear cell renal cell carcinoma” in volume 499 at pages 43–49 and selecting the supplementary information. Within this supporting information is a downloadable batch of files entitled “Supplementary Data” and within is a file entitled “Data_file_S2_clinical_dataset.xlsx” that contains all the data used herein. This data is publicly available and the samples were de-identified and encoded with TCGA sample codes before publication. The TCGA data concerning genomic and clinical information is organized into two categories: one that is openly accessible to the public and one that has controlled access, information is available only to qualified researchers obligated to secure the data. The open access data set and has passed the criteria for unrestricted publication with the following statement “No restrictions; all data available without limitations” listed at http://cancergenome.nih.gov/abouttcga/policies/publicationguidelines.

The Cancer Genome Atlas (TCGA - http://cancergenome.nih.gov/) KIRC Data Retrieval

Data was retrieved from the Cancer Genome Atlas using the TCGA data portal to download the Infinium HumanMethylation27 BeadChip data for the 199 tumour and associated tumour normal samples for which the Infinium Methylation27 arrays had been performed in the TCGA KIRC (Kidney Renal Clear Cell Carcinoma) project. This comprised the following records: TCGA-A3-3306, 3308, 3311, 3313, 3316–3317, 3319–3320, 3322–3326, 3328–3329, 3331, 3335–3336, 3339, 3346, 3352, 3359, 3363, 3365, 3372, 3374, 3378, 3380, 3382–3383, 3387, 3394, 3395, 3391, 3392 (n = 34), TCGA-B0-4833–4834, 4836–4839, 5073, 5077, 5081, 5084–5085, 5083 (n = 12), TCGA-B2-3923–3924, 4096–4099, 4102 (n = 3), TCGA-B8-4143, 4154 (n = 2), TCGA-BP-4150–4167, 4169, 4173–4174, 4176, 4177, 4177, 4179, 4181, 4184–4185, 4187, 4190, 4195–4196, 4197, 4198, 4199–4199, 4197, 4200, 4202 (n = 35) and TCGA-CJ-4854, 4857–4858, 4860–4862 (n = 6). Data was retrieved from the Cancer Genome Atlas using the TCGA data portal to download the clinical data and Infinium HumanMethylation450 BeadChip data for the 160 tumour and associated tumour normal samples for which the Infinium Methylation27 arrays had been performed in the TCGA KIRC project. This comprised the following records: TCGA-A3-3357, 3367, 3370, 3373, 3376, 3385 (n = 6), TCGA-B0-4638, 4690–4691, 4693–4694, 4696–4699, 4701, 4703, 4706–4707, 4710, 4712–4714, 4718, 4810–4811, 4813–4819, 4821–4824, 4823–4824, 4827–4828, 4841–4849, 4852, 4945, 5080, 5083, 5092, 5094–5100, 5102, 5104–5110, 5113, 5115–5117, 5119–5121, 5400, 5402, 5710–5713 (n = 74), TCGA-BP-4177, 4760, 4770, 4782, 4795, 4901, 4993, 5010, 5168–5170, 5173–5178, 5180–5196, 5198–5202 (n = 37), TCGA-CJ-4869, 4862, 4897, 4901–4905, 4907–4908, 4912–4913, 4916, 4918, 4920, 4923 (n = 16), TCGA-CZ-4853, 4856, 4859, 4863–4866, 5451–5470 (n = 27).

Infinium BeadChip Data Analysis

After all the data was downloaded all the probes that represented the 77 previously published kidney cancer-associated hypermethylated gene candidates (Table S1 in File S1) were selected. In the case of the HumanMethylation450 BeadChip arrays only probes that were described by the annotation files as being within the CpG island were selected. In the case of the HumanMethylation450 BeadChip arrays only probes that were described by the annotation files as being within the CpG island were selected.

Hypermethylation Affects Survival in KIRC Patients

evidence of tumor-specific promoter hypermethylation in RCC than have been identified by various methodologies [11]. Traditionally, these studies used targeted gene specific analyses, such as methylated-specific PCR (MSP) and combined bisulfite restriction analysis (CoBRA), but more recently several different types of non-specific global methylation aberration assessment assays have been used to assess RCC. These include an RCC cell-line specific assay assessing gene up-regulation post 5-aza-2’-deoxycytidine demethylation treatment by gene expression micro-arrays [16], methylated DNA immunoprecipitation (MeDIP) analysis of tumors [17] and analyzing tumors using two different BeadChip arrays, the cancer gene specific goldengate array [18] and the global Infinium HumanMethylation27 BeadChip [19]. This wealth of investigation has provided a large number of potentially important methylated genes within sporadic RCC but very little consensus on which genes are truly important or hold true for larger populations and whether any single methylated gene or group of genes have relevance to clinical outcome. Thus, a great opportunity is provided to this field by the publication of the TCGA KIRC (Kidney Renal Clear Cell Carcinoma) data. These data include 199 CCRCC tumor:normal paired analyses using the Infinium HumanMethylation27 BeadChip and 160 CCRCC tumor:normal paired analyses using the newer and more extensive the Infinium HumanMethylation450 BeadChip. Additionally, there is somatic mutation analysis data and chromosome copy number alteration data for a large number of CCRCC tumor that can used to assess any given candidate gene for evidence of alternative methods of loss or for potentially relevant second hits to partially methylated tumor suppressor genes. The object of this manuscript is to assess a list known RCC candidate methylation partially methylated tumor suppressor genes. The object of this manuscript is to assess a list known RCC candidate methylation
would represent significant changes in methylation. Hypermethylation of a probe was considered significantly frequent for either cohort if it occurred in 5% or more of tumors.

**Assessment of Chromosomal Deletion/Amplification Data, Somatic Mutation Data and Clinical Information**

The chromosomal deletion and amplification data and clinical information was freely available from the supplementary files provided by the TCGA KIRC project Nature publication [6]. The somatic mutation data was acquired using the cBioPortal for Cancer Genomics provided by the Memorial Sloan-Kettering Cancer Center (http://www.cbioportal.org/public-portal/) and analyzing the Kidney Renal Clear Cell Carcinoma (TCGA, in press) data set. Survival analysis for somatic mutations was performed using the inbuilt cBioPortal software.

**Statistical Analysis**

The Kaplan-Meier survival curve analysis and the Cox proportional-hazard regression was performed using the MedCalc statistical software (http://www.medcalc.org/index.php). Cox proportional-hazard analysis was performed with the "Enter" method (i.e. enter all variables in the model in one single step, without checking) and in each analysis the hypermethylation of a single probe or gene was compared to tumor stage, tumor grade, maximum tumor dimension and patient gender. Correction for multiple analyses was performed using False Discovery Rate (FDR) modulation of p-values for the Kaplan-Meier survival curve analysis. All statistics were considered significant with a p-value ≤0.05.

**Results**

The TCGA KIRC (Kidney Renal Clear Cell Carcinoma) project ran HumanMethylation27 bead arrays on 199 clear cell Renal Cell Carcinoma (CCRCC) tumor/normal paired samples and HumanMethylation450 bead arrays on a further 160 separate CCRCC tumor/normal paired samples, most of which were also assessed for chromosomal copy number loss/gain and somatic mutation (sample ids listed in methods). Importantly, clinical data was available for 326 of these samples. This provides a unique tool for the assessment of the previously published kidney cancer-associated hypermethylated gene candidates from which 77 genes were chosen (Table S1 in File S1).

**Tumor-specific Hypermethylation Analysis of the 199 CCRCC HumanMethylation27 BeadChip Cohort**

Initial analysis was performed using the 199 CCRCC tumor/normal paired samples assessed by the HumanMethylation27 BeadChip arrays. For the purpose of this analysis only probes that were unmethylated in the normal state were of interest thus the average β-value across the associated normals for any probe had to be less than or equal to 0.25. To assess tumor-specific hypermethylation a difference value (D-value) was calculated for each probe in each tumor by subtracting the associated normal value from the tumor β-value in each case. A nominal D-value of +0.35 was selected as representing significantly increased tumor-specific hypermethylation and a frequency greater than or equal to 5% was nominally considered significantly frequent.

For the initial analysis, all 287 probes pertaining to the 77 genes in the hypermethylated candidate list were selected and assessed by the above criteria (Table S2 in File S1). The HumanMethylation27 BeadChip arrays contain an average of 2 probes per gene with some selected genes represented by larger numbers of probes, the selected genes had a higher than average representation of 3.73 probes per gene. From these 287 probes, 47 probes were considered positive for hypermethylation representing 29 different genes (Table 1). Twelve genes had two or more hypermethylated probes (5 probes - BNC1, 3 probes - CDKN2A, GSTP1, SFRP1, 2 probes - COL1A2, DKK1, ESRI, FBX2, GNB4, OVOL1, SLC34A2, TMEM52) and 9 genes had probes that were hypermethylated in greater than 15% of tumors (BNC1 - 22.1%, COL1A2 - 16.1%, FBX2 - 40.2% & 24.1%, GREM1 - 16.1%, PCDH10 - 19.1%, SFRP1 - 16.1%, SLC34A2 - 30.2% & 16%, SST - 16.8%, TM6SF1 - 33.2%).

Tumor-specific methylation of the VHL gene is an expected event and was observed in a single probe, but with a frequency slightly below the expected levels of hypermethylation. Further investigation of this highlighted a potential issue with the HumanMethylation27 BeadChip array that the probes may not be positioned within the predicted CpG island. In fact, for the VHL gene all 7 of the probes associated with VHL occur downstream of the CpG with only the closest probe demonstrating frequent tumor-specific hypermethylation (Figure 1A). In contrast, another commonly reported CCRCC hypermethylated gene, SFRP1, has 3 of its 5 associated probes within the predicted CpG island and all three demonstrate frequent tumor-specific hypermethylation (Figure 1B). This suggests that probe position can affect the analysis and that assessment of the CpG island probes may provide more relevant results and that the HumanMethylation450 BeadChip arrays may provide more substantial results as there are a larger number of probes than fall within the CpG islands as demonstrated with the VHL CpG island (Figure 1A). It is notable that the BNC1 gene has 7 associated probes, similar to VHL, but 5 of these are within the predicted CpG island and has the largest number of frequently hypermethylated probes (Figure S1 in File S1). Interestingly, only four of the five BNC1 CpG island probes are frequently hypermethylated and the remaining probe is positioned between other hypermethylated probes, possibly indicating variation can be present across the CpG island.

**Tumor-specific Hypermethylation Analysis of the 160 CCRCC HumanMethylation450 BeadChip Cohort**

The analysis of the HumanMethylation450 BeadChip cohort was slightly modified to limit probe selection to those that described as being within the predicted CpG islands. This identified 632 probes with an average associated normal β-value of 0.25, of which 182 probes representing 45 genes demonstrated tumor-specific hypermethylation in ≥5% of tumors (Table S3 in File S1). For each of these 45 genes the most frequently hypermethylated probe was assessed as well as the average frequency for all hypermethylated probes for genes with multiple hypermethylated probes (Table 2). These 45 genes were represented by an average of 9.2 CpG island probes per gene with a range of 1 to 25 probes. The percentage of these CpG island probes that demonstrated frequent hypermethylation in any of the 45 genes ranged from 6.3% (1 out of 16 probes in RASSF5) to 100% (10 out of 10 probes with FBX2) (Table S4 in File S1). Thirteen genes demonstrated a single probe hypermethylated in greater than 20% of tumors (ATP5G2 - 35.6%, DKK1 - 24.4%, DKK2 - 26.9%, FBX2 - 52.5%, GUCY2D - 28.1%, PCDH10 - 62.5%, PDK1 - 31.9%, ROBO1 - 27.5%, SFRP1 - 33.8%, SLC34A2 - 26.9%, SST - 24.4%, TM6SF1 - 36.9%, ZSCAN18 - 55.0%) and furthermore, eight of these genes (underlined) had multiple hypermethylated probes with an average hypermethylation frequency in tumors of greater than 20% (Table 2).

An important use of the HumanMethylation450 BeadChip cohort was to confirm the results of the HumanMethylation27 BeadChip cohort. Thus, there were 23 genes that were frequently hypermethylated (≥5%) in both cohorts (Figure S2 in File S1) and
### Table 1. Analysis of the Tumor-Specific Probe Hypermethylation in the Candidate Genes for the 199 TCGA RCC Tumor/Normal Pairs Present in the HumanMethylation27 BeadChip Cohort.

| Gene Symbol | Infinium Probe ID | Percentage of 199 Tumors with Probe Difference Values ≥0.35 | Average Associated Normal p-Value |
|-------------|-------------------|----------------------------------------------------------|----------------------------------|
| BMP4        | cg14310034        | 8.0%                                                     | 0.08                             |
| BNC1        | cg18952647        | 22.1%                                                    | 0.10                             |
| BNC1        | cg19988449        | 11.6%                                                    | 0.12                             |
| BNC1        | cg15736165        | 11.6%                                                    | 0.21                             |
| BNC1        | cg10398682        | 11.1%                                                    | 0.23                             |
| BNC1        | cg17051321        | 6.5%                                                     | 0.11                             |
| CCDC8       | cg15984661        | 5.5%                                                     | 0.15                             |
| CDH1        | cg24765079        | 5.5%                                                     | 0.20                             |
| CDKN2A      | cg09099744        | 11.1%                                                    | 0.09                             |
| CDKN2A      | cg10895543        | 10.1%                                                    | 0.15                             |
| CDKN2A      | cg07752420        | 9.0%                                                     | 0.13                             |
| CDKN2A      | cg18511007        | 16.1%                                                    | 0.17                             |
| CDKN2A      | cg25300386        | 12.1%                                                    | 0.19                             |
| DKK1        | cg07684796        | 8.5%                                                     | 0.11                             |
| DKK1        | cg12621514        | 7.0%                                                     | 0.17                             |
| DLEC1       | cg23881725        | 12.1%                                                    | 0.20                             |
| ESR1        | cg20253551        | 5.0%                                                     | 0.13                             |
| ESR1        | cg02720618        | 5.0%                                                     | 0.14                             |
| FBN2        | cg27223047        | 40.2%                                                    | 0.13                             |
| FBN2        | cg25084878        | 24.1%                                                    | 0.24                             |
| GNB4        | cg17483510        | 9.0%                                                     | 0.19                             |
| GNB4        | cg09997760        | 5.5%                                                     | 0.04                             |
| GREM1       | cg21296230        | 16.1%                                                    | 0.09                             |
| GSTP1       | cg04920951        | 13.6%                                                    | 0.10                             |
| GSTP1       | cg02659086        | 5.0%                                                     | 0.06                             |
| GSTP1       | cg09038676        | 5.0%                                                     | 0.18                             |
| GUCY2D      | cg25465406        | 8.0%                                                     | 0.10                             |
| HOXB13      | cg15786837        | 6.5%                                                     | 0.09                             |
| LSAMP       | cg14294758        | 8.0%                                                     | 0.10                             |
| OVOL1       | cg20909686        | 14.1%                                                    | 0.18                             |
| OVOL1       | cg13496736        | 11.1%                                                    | 0.06                             |
| PCDH8       | cg20366906        | 19.1%                                                    | 0.14                             |
| PRPM        | cg27420236        | 9.0%                                                     | 0.08                             |
| SCUBE3      | cg21604042        | 13.1%                                                    | 0.07                             |
| SFRP1       | cg22418909        | 16.1%                                                    | 0.08                             |
| SFRP1       | cg13398291        | 11.1%                                                    | 0.09                             |
| SFRP1       | cg15839448        | 7.0%                                                     | 0.05                             |
| SFRP2       | cg23207990        | 9.0%                                                     | 0.07                             |
| SLC34A2     | cg19616230        | 30.2%                                                    | 0.07                             |
| SLC34A2     | cg21200703        | 16.1%                                                    | 0.17                             |
| SST         | cg02164046        | 16.6%                                                    | 0.08                             |
| TM6SF1      | cg14696396        | 35.2%                                                    | 0.07                             |
| TMPPRSS2    | cg24901042        | 12.1%                                                    | 0.17                             |
| TMPPRSS2    | cg02613803        | 5.0%                                                     | 0.06                             |
| UCHL1       | cg24715245        | 7.0%                                                     | 0.11                             |
| VHL         | cg22782492        | 6.0%                                                     | 0.10                             |
| WIF1        | cg19427610        | 8.0%                                                     | 0.05                             |

doi:10.1371/journal.pone.0085621.t001
7 genes that were hypermethylated in $\geq 15\%$ of tumors for both cohorts, \textit{BNC1}, \textit{FBN2}, \textit{PCDH8}, \textit{SFRP1}, \textit{SLC34A2}, \textit{SST}, \textit{TM6SF1} (Tables 1 & 2), that represent good potential epigenetic biomarkers for CCRCC.

**Assessment of Chromosomal Loss/Deletion and Somatic Mutation of the Hypermethylated Genes in the TCGA Project Tumors**

The published TCGA KIRC project data includes information on common regions of chromosomal deletion and amplification, at both the whole/partial chromosome and focal level, as well as data on somatic mutation in the tumors. This data was assessed on the assumption that frequent chromosomal deletion or somatic mutation could either occur in conjunction with hypermethylation, possibly as a “second hit”, or as an alternative method of gene silencing and thus refine the list of hypermethylated genes to those of greater potential importance. Currently not all TCGA KIRC project samples have been analyzed for all these different data types and so the data does not exactly match the specific 359 CCRCC tumors that were analyzed for methylation but in both
| Gene Symbol | Percentage of Diff. Values ≥0.35 in Tumors for the Most Hypermethylated Gene-Associated Probe (Infinium Probe ID) | No. of Probes Methylated in >5% of tumors out of all the Gene-Associated CpG Island Probes | Average Percentage of Diff. Values ≥0.35 in Tumors for all Positive Gene-Associated Probes |
|-------------|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| ATP5G2      | 35.63% (cg13691247)                                                                                            | 4 out of 10                                                                        | 26.70%                                                                            |
| BMP4        | 8.13% (cg06162372)                                                                                            | 2 out of 14                                                                         | 7.50%                                                                             |
| BNC1        | 18.75% (cg06523224)                                                                                            | 13 out of 20                                                                        | 10.20%                                                                            |
| BTG3        | 5.00% (cg02652260)                                                                                            | 1 out of 9                                                                          | n/a                                                                               |
| CCDC8       | 8.75% (cg06747432)                                                                                            | 1 out of 1                                                                          | n/a                                                                               |
| CDH13       | 7.50% (cg06747377)                                                                                            | 2 out of 7                                                                          | 7.20%                                                                             |
| COL14A1     | 6.88% (cg04242021)                                                                                            | 1 out of 6                                                                          | n/a                                                                               |
| CORO6       | 5.00% (cg04568355)                                                                                            | 1 out of 7                                                                          | n/a                                                                               |
| CST6        | 10.00% (cg04327181)                                                                                           | 1 out of 5                                                                          | n/a                                                                               |
| DKX1        | 24.38% (cg08812555)                                                                                           | 5 out of 7                                                                          | 14.00%                                                                            |
| DKX2        | 26.88% (cg13139972)                                                                                           | 3 out of 5                                                                          | 12.70%                                                                            |
| DKX3        | 6.88% (cg19867649)                                                                                            | 3 out of 13                                                                         | 5.80%                                                                             |
| DLEC1       | 18.13% (cg20684180)                                                                                           | 3 out of 6                                                                          | 10.80%                                                                            |
| EPB41L3     | 18.75% (cg07352438)                                                                                           | 11 out of 13                                                                        | 10.50%                                                                            |
| FB2N        | 52.50% (cg27223047)                                                                                           | 10 out of 10                                                                        | 23.80%                                                                            |
| GATA5       | 13.13% (cg09339194)                                                                                           | 14 out of 25                                                                        | 7.10%                                                                             |
| GNB4        | 15.00% (cg12872693)                                                                                           | 4 out of 7                                                                          | 11.30%                                                                            |
| GREM1       | 13.75% (cg21296230)                                                                                           | 3 out of 7                                                                          | 10.20%                                                                            |
| GSTP1       | 12.50% (cg04920951)                                                                                           | 4 out of 5                                                                          | 11.60%                                                                            |
| GUCY2D      | 28.13% (cg04157161)                                                                                           | 2 out of 8                                                                          | 20.90%                                                                            |
| HOXC13      | 7.50% (cg07892422)                                                                                            | 2 out of 9                                                                          | 6.30%                                                                             |
| KLHL35      | 15.00% (cg12001148)                                                                                           | 2 out of 7                                                                          | 10.00%                                                                            |
| KRT19       | 8.13% (cg11462865)                                                                                           | 2 out of 3                                                                          | 7.50%                                                                             |
| LOXL1       | 6.25% (cg22590761)                                                                                            | 1 out of 11                                                                         | n/a                                                                               |
| MGMT        | 7.50% (cg02022136)                                                                                            | 1 out of 14                                                                         | n/a                                                                               |
| OVOL1       | 18.75% (cg20909686)                                                                                           | 2 out of 11                                                                         | 14.40%                                                                            |
| PCDH8       | 62.50% (cg05336395)                                                                                           | 11 out of 13                                                                        | 27.20%                                                                            |
| PDLIM4      | 31.88% (cg02033258)                                                                                           | 2 out of 2                                                                          | 23.10%                                                                            |
| PTG52       | 6.25% (cg13986130)                                                                                            | 1 out of 10                                                                         | n/a                                                                               |
| QPCT        | 15.00% (cg08786077)                                                                                           | 5 out of 8                                                                          | 12.10%                                                                            |
| RASSF5      | 9.38% (cg18328206)                                                                                            | 1 out of 16                                                                         | n/a                                                                               |
| ROBO1       | 27.50% (cg21865845)                                                                                           | 3 out of 7                                                                          | 16.50%                                                                            |
| RPRM        | 16.88% (cg26649384)                                                                                           | 8 out of 12                                                                         | 10.30%                                                                            |
| SCUBE3      | 6.25% (cg00347904)                                                                                            | 1 out of 6                                                                          | n/a                                                                               |
| SFRP1       | 33.75% (cg24319902)                                                                                           | 6 out of 8                                                                          | 16.90%                                                                            |
| SFRP2       | 18.75% (cg22178613)                                                                                           | 8 out of 19                                                                         | 8.60%                                                                             |
| SLC34A2     | 26.88% (cg27513574)                                                                                           | 7 out of 7                                                                          | 22.10%                                                                            |
| SLIT2       | 5.00% (cg13078140)                                                                                            | 2 out of 12                                                                         | 5.00%                                                                             |
| SST         | 24.38% (cg02164046)                                                                                            | 3 out of 3                                                                          | 17.30%                                                                            |
| TM6SF1      | 36.88% (cg26460092)                                                                                           | 5 out of 7                                                                          | 24.80%                                                                            |
| TMPRSS2     | 18.75% (cg16084872)                                                                                           | 4 out of 10                                                                         | 12.00%                                                                            |
| UCHL1       | 11.88% (cg070687560)                                                                                          | 5 out of 7                                                                          | 9.30%                                                                             |
| VHL         | 5.00% (cg15267345)                                                                                            | 1 out of 3                                                                          | n/a                                                                               |
| WIF1        | 17.50% (cg26397188)                                                                                           | 4 out of 6                                                                          | 15.20%                                                                            |
| ZSCAN18     | 55.00% (cg14231297)                                                                                           | 7 out of 18                                                                         | 24.40%                                                                            |
cases represents data from over 400 CCRCC tumors. The 51 genes that demonstrated hypermethylated probes in either of the two BeadChip cohorts were mapped onto the human chromosomes, with those genes hypermethylated in both cohorts highlighted in bold (Figure S3 in File S1). Added to this were the regions of whole/partial chromosomal loss/deletion (with blue bars) or amplification (with red bars) and regions of focal loss (blue arrows) or gain (red arrows) (Figure S3 in File S1). This identified four genes that mapped to regions of chromosomal and focal loss, VHL ( Chr.3p), ROBO1 ( Chr.3p), SFRP1 (Chr.3p) and CDKN2A (Chr.9p), as well as a further three genes that mapped to regions of chromosomal loss, DLEC1 (Chr.3p), ESR1 ( Chr.6q), PCDH8 (Chr.13q) (Figure 2, Figure S3 in File S1).

Somatic mutation was a rare event for any of the hypermethylated genes with the exception of the VHL gene that demonstrated the expected high level of mutation with 293 out of 424 (55.4%) tumors having detectable mutation. A small number of genes demonstrated low levels of somatic mutation with a frequency of approximately 1% or greater; BNC1 (0.9%), DLEC1 (0.9%), PTGS2 (0.9%), CDKN2A (1.2%), COL1A2 (1.4%) and FBN2 (3.1%) (Figure S4 in File S1).

Survival Analysis of the Hypermethylated Genes in the TCGA Project Patients

The published TCGA KIRC project data includes clinical information for a large number of the patients from which the CCRCC tumors were excised. Complete clinical data, including gender, tumor size, grade, tumor stage, patient survival status and duration from surgery to last check-up or death, was available for 181 patients from the HumanMethylation27 BeadChip cohort. Table S5 in File S1 and 145 patients from the HumanMethylation450 BeadChip cohort (Table S6 in File S1). In all cases the presence of tumor-specific hypermethylation was compared to the duration in days of patient survival (recurrence was not used as a factor) using Kaplan-Meier survival curves and selected probes genes were further assessed by Cox proportional-hazards regression to see if the hypermethylation had any significant value as an independent marker for poorer survival in comparison to gender, maximum tumor dimension, tumor grade and tumor stage.

For HumanMethylation27 BeadChip cohort this analysis was performed considering each hypermethylated probe separately and hypermethylation of 15 out of the 48 probes were demonstrated to predict for worse survival (Table 3). To correct for false positives due to multiple analyses a false discovery rate (FDR) modification was applied and 6 probes representing 4 genes, SFRP1 (3x), BNC1, PCDH8 and SCUBE3 remained statistically significant (Figure 3). Cox proportional-hazards regression for these 6 probes demonstrated that 3 probes represented the most statistically significant indicators of survival compared to tumor stage, grade, maximum dimension or patient gender; SFRP1 (p = 0.009, HR = 2.40, CI = 1.25–4.64), BNC1 (p = 0.004, HR = 2.36, CI = 1.32–4.20) and PCDH8 (p = 0.012, HR = 2.13, CI = 1.18–3.82) (Table S7 in File S1). The remaining 3 genes were all statistically significant indicators, but were less significant than tumor stage (Table S7 in File S1).

To confirm these predictions similar analysis was performed upon the HumanMethylation450 BeadChip cohort. When the most hypermethylated probe for each gene was analyzed 12 out of the 45 probes were demonstrated to predict for worse survival with 5 genes still remaining statistically significant after correction for multiple analyses (Figure S5 and Table S8 in File S1). By Cox proportional-hazards regression, two probes were statistically significant indicators, but were both less significant than tumor grade; BNC1 (p = 0.050, HR = 1.76, CI = 1.00–3.00) and SCAN18 (p = 0.020, HR = 1.87, CI = 1.07–3.24) (Table S9 in File S1). This strengthened the potential importance of BNC1 hypermethylation as a indicator for poorer patient survival.

Due to the increased number probes present in the HumanMethylation450 BeadChip array, the analysis was repeated for genes with multiple hypermethylated probes such that a proportion of the probes had to be hypermethylated in each tumor before that tumor was considered positive for hypermethylation. The proportions were assigned such that genes with 2–4 hypermethylated probes needed a minimum of 2 per tumor, genes with 5–6 hypermethylated probes needed a minimum of 3 per tumor and genes with 7 or more hypermethylated probes needed a minimum of 4 per tumor. This was performed assuming the results might be more comparable to other studies where the methodologies always assess multiple CpGs and might provide a more accurate view of the CpG island methylation. Subsequently, 11 out of the 26 hypermethylated genes were demonstrated to predict for worse survival with 4 genes, SFRP1, GATA5, GREM1 and BNC1, still remaining statistically significant after correction for multiple analyses (Table 4, Figure 4). Cox proportional-hazards regression for hypermethylation of these 4 genes demonstrated that 3 genes represented statistically significant indicators of survival, but were all less significant than tumor stage; SFRP1 (p = 0.036, HR = 1.92, CI = 1.05–3.50), GREM1 (p = 0.007, HR = 3.05, CI = 1.36–6.86) and BNC1 (p = 0.033, HR = 1.99, CI = 1.06–3.75) (Table S9 in File S1). This data demonstrated that hypermethylation of either SFRP1 or BNC1 were independent markers for poor patient survival in both cohorts.
Kaplan-Meier survival curves were calculated for all of the tumor-specific hypermethylated probes within the HumanMethylation27 BeadChip cohort and these graphs represent the probes for which the p-value remained significant after false discovery rate (FDR) correction for multiple analyses. The percentage of hypermethylation (Meth) is representative of the 181 CCRCC tumor/normal pairs for which clinical information was available. The relevant BeadChip probe is listed with the gene name.

Table 3. Kaplan Meier Survival Analysis for the HumanMethylation27 BeadChip Cohort.

| Gene Name | HyperMeth. Probe | HyperMethylation (% of 181 tumors) | p-value | Hazard Ratio | 95% Confidence Interval | False Discovery Rate corrected p-value |
|-----------|------------------|-----------------------------------|---------|--------------|-------------------------|---------------------------------------|
| BNC1      | cg18952647       | 20.44%                            | <0.0001 | 2.9043       | 1.4731 to 5.7260        | <0.0001                               |
| SFRP1     | cg22418909       | 16.02%                            | <0.0001 | 3.0984       | 1.4628 to 6.5630        | <0.0001                               |
| SFRP1     | cg13398291       | 9.94%                             | 0.0001  | 3.2181       | 1.2628 to 8.2007        | 0.0003                                |
| SFRP1     | cg15839448       | 6.08%                             | 0.0035  | 2.8845       | 0.9106 to 9.1371        | 0.0140                                |
| PCDH8     | cg20366906       | 18.23%                            | 0.0047  | 2.2150       | 1.0929 to 4.4891        | 0.0235                                |
| SCUBE3    | cg21604042       | 13.26%                            | 0.0059  | 2.2382       | 1.0534 to 4.7553        | 0.0354                                |
| UCHL1     | cg24715245       | 5.52%                             | 0.0087  | 2.7507       | 0.8208 to 9.2179        | 0.0609                                |
| TMSF1     | cg14696396       | 35.36%                            | 0.0089  | 1.9721       | 1.1484 to 3.3867        | 0.0712                                |
| GNB4      | cg09997760       | 4.97%                             | 0.0170  | 2.6824       | 0.7354 to 9.7838        | 0.1530                                |
| BNC1      | cg10398682       | 9.94%                             | 0.0213  | 2.1786       | 0.8753 to 5.4223        | 0.2130                                |
| OVL1      | cg13496736       | 9.94%                             | 0.0245  | 2.1399       | 0.8655 to 5.2905        | 0.2695                                |
| BMP4      | cg14310034       | 6.63%                             | 0.0336  | 2.2939       | 0.7522 to 6.9951        | 0.4032                                |
| SFRP2     | cg23207990       | 8.84%                             | 0.0427  | 2.0543       | 0.8043 to 5.2472        | 0.5551                                |
| PRM       | cg27402036       | 8.29%                             | 0.0436  | 2.1148       | 0.7730 to 5.7858        | 0.6104                                |
| WIF1      | cg19427610       | 7.73%                             | 0.0436  | 2.1156       | 0.7731 to 5.7889        | 0.6540                                |

*181 patients from the HumanMethylation27 BeadChip Cohort had the appropriate clinical data.

doi:10.1371/journal.pone.0085621.t003
Clear cell renal cell carcinoma (CCRCC) has been shown to associate with a wide spectrum of tumor-specific genetic and epigenetic alterations that can result in loss or inactivation of numerous tumor suppressor genes (TSGs). The investigation and identification of which TSG losses are most associated with tumor progression or patient survival should therefore aid in the management of this therapeutically resistant disease. CCRCC has a very strong association with the tumor-specific loss of chromosome 3p and mutation/inactivation, including promoter hypermethylation, of the \textit{VHL} gene on the remaining chromosome. In fact this association with chromosome 3p loss has recently been strengthened by several publications demonstrating that 4 out of five (\textit{VHL, PBRM1, SETD2} and \textit{BAP1}) of the most frequently mutated genes associated with CCRCC are on chromosome 3p \cite{6-10} and that the mutation of either \textit{SETD2}, \textit{BAP1} or \textit{PBRM1} associates with poorer prognosis or progression in those patients \cite{6,20,21}.

Although these comprehensive analyses have demonstrated and reinforced the importance of these 3p genes, there are still only a small number of frequently (>5%) mutated genes associated with CCRCC. In contrast, a far larger number of genes have been demonstrated to have tumor-specific CpG island hypermethylation in CCRCC and other histological sub-types of kidney cancer, including several genes that demonstrate promoter hypermethylation in greater than 20% of cases \cite{11}. Unlike sequence analysis, where a relatively uniform method of assessment is used, methylation analysis has been performed by various different methods that may not be comparable and largely on relatively small numbers of samples. Many methodologies only assess a small number of CpGs per CpG island that are expected to be representative of the methylation levels of the entire CpG island. For Methylation-Specific PCR (MSP) it is limited to those CpGs within the primers, while in combined bisulfite restriction analysis (CoBRA) by the number of CpGs within the relevant restriction cut sites. More comprehensive analysis of CpG islands can be achieved by bisulfite sequencing or pyrosequencing, but these methodologies are very time consuming and allow for analysis of only a small fragment of the genome each time. Thus confirmation of tumor-specific methylation in novel large cohorts by alternative methodologies is very valuable in demonstrating the importance of the hypermethylation in any given gene.

The TCGA KIRC (Kidney Renal Clear Cell Carcinoma) project data provides a large amount of raw and processed data including analysis of methylation using the BeadChip array technology. This technology uses probes that investigate only a single CpG per probe, which is obviously restrictive, but the
number of probes investigated is only limited by the current state of the technology. Thus during the time the TCGA KIRC data was being gathered early samples were analyzed by an initial array (HumanMethylation27) containing ~27,000 probes, but later samples used a newer, larger array (HumanMethylation450) containing ~450,000 probes that provided a greater intensity to the analysis. To date, no other CCRCC samples have been assessed by the array HumanMethylation27 BeadChip array and only a single study, from which we obtained some of the candidate hypermethylated genes, has used the array HumanMethylation27 BeadChip array [19]. This provides a large amount of data for assessment and importantly both the tumor and associated normals were assessed allowing for the calculation of tumor-specific gain of hypermethylation (tumor \(\beta\)-value – normal \(\beta\)-value) that should hopefully control for the fact that CpG island methylation levels can increase with age in normal tissue [22].

By splitting the patients into two cohorts based on the use of the two different BeadChip arrays we could both look confirmatory hypermethylation of genes occurring in both cohorts and compare the usefulness of each array. This highlighted one of the known weaknesses with the original HumanMethylation27 BeadChip array that most genes are only represented by a few probes and that the positioning of those probes in respect to the CpG island might affect the result of the analysis. This could easily result in the underestimation or complete lack of assessment of methylation for a gene. This is exemplified by comparison of the position of the probes associated with the VHL gene and the SFRP1 gene in the HumanMethylation27 BeadChip array and demonstrates the advantages of using the HumanMethylation450 BeadChip array. The increased number of probes within the HumanMethylation450 BeadChip array allowed for the restriction of probe selection to those within the CpG island and for the assessment of genes based on the presence of multiple hypermethylated probes. This approach seems justified as the survival analysis using genes with multiple probes produced 4 statistically significant genes all of which have been previously associated with poor patient survival and tumor progression. Two recent publications demonstrated that GATA5 hypermethylation in RCC associated with status of metastasis, progressive disease and shortened progression-free survival [23] and that GREM1 hypermethylation in CCRCC is associated with increased Fuhrman grade and decreased overall survival [24]. While the remaining two genes, BNC1 and SFRP1, are discussed in greater length below.

Due to the potential limitations of using either array we considered genes that showed frequent methylation in both cohorts to have demonstrated strong evidence of tumor specific methylation in CCRCC and those for which only one cohort showed frequent methylation to have demonstrated weaker strong evidence of tumor specific methylation in CCRCC. These genes that were only identified by one platform included well known tumor suppressors such as CDKN2A and RASSF5 that obviously warrant investigation, but did not meet the criteria for this specific study. These limitations are particularly relevant to the HumanMethylation27 BeadChip arrays and subsequent studies are likely to use the newer platforms, but the currently available data is still important and useful. Thus, data was not used to discredit or disagree with any previously published data concerning a genes methylation frequency as we could not be certain that this methodology accurately assessed all target genes.

This analysis was successful in confirming a large number of the predicted hypermethylated genes within the TCGA KIRC data, but one of the purposes of using this data was to ingrate in the other analyses, such as chromosomal loss or somatic mutation, to highlight particularly important genes and to use the clinical information to attempt to identify epigenetic markers of poorer patient survival. From this analysis 4 genes (FBN2, PCDH8, BNC1 and SFRP1) stand out as either particularly strong epigenetic biomarkers of kidney cancer or as significant predictors of patient outcome. One form of analysis that was not performed due to a lack of data was the assessment of correlation between promoter hypermethylation and mRNA expression. Although a large number of the tumor samples had been analyzed for mRNA expression by RNASeq analysis, only a small number of tumor/normal pairs had been assessed (n = 69) and of those only a third (n = 22) had been assessed for methylation. For these selected 4 genes the mRNA expression levels were compared between the methylated tumors vs the non-methylated tumors within the HumanMethylation450 BeadChip cohort and demonstrated decreased expression within the methylated tumors (Figure S6 in File S1). That the PCDH8 and SFRP1 genes demonstrated mild

| Gene Name | HyperMeth. Probes required per gene | HyperMethylation (% of 145 tumors) | p-value | Hazard Ratio | 95% Confidence Interval | False Discovery Rate corrected p-value |
|-----------|------------------------------------|----------------------------------|--------|-------------|------------------------|--------------------------------------|
| SFRP1     | ≥3 out of 6                        | 13.10%                           | 0.0010 | 2.5136      | 1.1429 to 5.5278       | 0.0010                               |
| GATA5     | ≥4 out of 14                       | 7.59%                            | 0.0015 | 2.8207      | 1.0170 to 7.8236       | 0.0030                               |
| GREM1     | ≥2 out of 3                        | 6.21%                            | 0.0035 | 3.0138      | 0.8511 to 10.672       | 0.0105                               |
| BNC1      | ≥4 out of 13                       | 12.41%                           | 0.0095 | 2.1732      | 0.9774 to 4.8323       | 0.0380                               |
| DKK2      | ≥2 out of 3                        | 8.97%                            | 0.0127 | 2.2806      | 0.9000 to 5.7789       | 0.0635                               |
| FBN2      | ≥4 out of 10                       | 28.28%                           | 0.0171 | 1.8109      | 1.0204 to 3.2139       | 0.1026                               |
| WIFI      | ≥2 out of 4                        | 16.55%                           | 0.0184 | 1.9052      | 0.9772 to 3.7144       | 0.1288                               |
| TM6SF1    | ≥3 out of 5                        | 26.21%                           | 0.0202 | 1.7914      | 1.0111 to 3.1738       | 0.1616                               |
| GUCY2D    | Both                               | 5.52%                            | 0.0207 | 2.5730      | 0.7214 to 9.1773       | 0.1863                               |
| GNB4      | ≥2 out of 4                        | 13.79%                           | 0.0211 | 2.0013      | 0.9236 to 4.3366       | 0.2110                               |
| RPM       | ≥4 out of 8                        | 6.90%                            | 0.0219 | 2.3031      | 0.8100 to 6.5488       | 0.2409                               |

*145 patients from the HumanMethylation450 BeadChip Cohort had the appropriate clinical data.
doi:10.1371/journal.pone.0085621.t004
decreases could potentially be a result of the unmethylated samples having the common chromosomal losses and thus also having low expression compared to normal kidney. Due to the lack of normal controls, this data was considered supportive but not substantial enough to draw conclusions from.

The Fibrillin 2 (FBN2) gene was very frequently hypermethylated in tumors from both cohorts with a single probe being hypermethylated in 40.2% of the HumanMethylation27 BeadChip cohort and 52.5% of the HumanMethylation450 BeadChip cohort and the gene demonstrated a relatively high somatic mutation rate (3.1%), although the effects of these mutations are yet to be elucidated. Hypermethylation of FBN2 has been previously reported in RCC (34%) [17] as well as several other cancer types including small cell lung cancer [25], esophageal squamous cell carcinoma [20] and colorectal cancer, in which it was potentially associated with hepatic metastasis [27]. Currently, the function of FBN2 protein is thought to be similar to the related FBN1 protein, they are both key components of human microfibrils that may affect regulation of TGF-β signaling. Loss of FBN1 has been demonstrated to result in excess activation of TGF-β [28] and this may also be true for FBN2 loss and aid malignancy by dysregulating the TGF-β signaling pathway. Although, hypermethylation of FBN2 demonstrated no correlation with patient survival it presents as potential biomarker for CCRCC.

The protocadherin β (PCDH8) gene was hypermethylated in both cohorts, with one cohort demonstrating hypermethylation in >20% of tumors, and resides on the frequently lost chromosome 13q region. PCDH8 hypermethylation correlated with poorer patient survival in one cohort where it represented a more significant prognostic marker for patient survival than tumor stage, grade or dimension, but was not statically significant in the second cohort, although a trend was present. Hypermethylation of PCDH8 has been previously reported in RCC (50%) [17] as well as in mantle cell lymphoma [29], breast carcinoma [30] and gastric cancer, including para-carcinomic but not normal gastric tissue [31]. In gastric cancer, PCDH8 hypermethylation was associated with lymph node metastasis that could be indicative of poorer survival outcome [31]. In these previous reports it was shown that either re-introduction of PCDH8 or treatment with the 5-aza-2'-deoxycytidine demethylating agent resulted in suppression of migration and promotion of apoptosis [30,31]. Although the 5-aza-2'-deoxycytidine treatment was non-specific, thus the activation of other hypermethylated tumor suppressors could be producing the effect, the re-introduction of PCDH8 demonstrates the specific importance of this gene. Cadherin molecules are known to be important for creating and maintaining proper tissue architecture and development and mutation of classic cadherins, such as E-cadherin, in several cancer types have shown them to function as tumor suppressors [32]. The exact function of PCDH8 protein is unknown, but there is increasing evidence for the importance of this family of proteins as potential tumor suppressors possibly via disruption of cell-cell communication necessary for tissue organization. Within the same gene cluster as PCDH8 there resides PCDH17 and PCDH20 that are both hypermethylated and homozygously deleted in esophageal squamous cell carcinoma [33] and lung cancer [34] respectively. Thus, PCDH8 hypermethylation presents as a good biomarker for CCRCC as well as a potential marker for poorer survival in patients and the initial evidence that re-expression of PCDH8, possibly via 5-aza-2'-deoxycytidine treatment, has a negative effect on tumors could be therapeutically beneficial in improving these patients’ survival outcomes.

The basonuclin 1 (BNC1) gene was hypermethylated in both cohorts with one cohort demonstrating hypermethylation in >20% of tumors and a small proportion of tumors demonstrated somatic mutation (0.9%). More importantly, BNC1 hypermethylation correlated with poorer patient survival in the HumanMethylation27 BeadChip cohort, where it represented a more significant prognostic marker for patient survival than tumor stage, grade or dimension, and in the HumanMethylation450 BeadChip cohort, where it was the only remaining statistically significant marker after tumor grade. Tumor-specific BNC1 hypermethylation has been previously reported in RCC (46%) [16] as well as in prostate, breast, lung and colon cancers [35]. It has also been reported in hematological malignances including lymphoblastic [36] and lymphocytic leukemia [37]. The previous study in RCC also associated BNC1 hypermethylation with poorer patient prognosis independent of tumor stage, grade or dimension [16]. BNC1 encodes a transcription factor that is important in the regulation of keratinocyte differentiation and why the loss this transcription factor would be advantageous to tumor growth or progression is yet to be elucidated. A recent publication demonstrated BNC1 to be a direct transcriptional target for the tumor suppressor gene p63, thus its loss could affect the tumor suppressing effect of p63, but in this publication the expression of BNC1 and p63 were elevated in the squamous cell carcinomas that were studied [38]. In spite of the lack of knowledge about its function, BNC1 hypermethylation presents as a good biomarker for CCRCC and an excellent marker for poor patient survival. This data confirms the previous observation of this using a much greater number of samples and, after further confirmation, this may prove to be one of the strongest epigenetic markers for poor survival in CCRCC.

The secreted frizzled-related protein 1 (SFRP1) gene was hypermethylated in both cohorts, with one cohort demonstrating hypermethylation in >20% of tumors, and resides on the frequently lost chromosome 8p region. SFRP1 hypermethylation strongly correlated with poorer patient survival in the HumanMethylation27 BeadChip cohort, with 3 of 6 statistically significant probes representing SFRP1. One probe represented a more significant prognostic marker for patient survival than tumor stage, grade or dimension and remaining two probes were statistically significant markers after tumor stage. In the HumanMethylation450 BeadChip cohort, hypermethylation of SFRP1 was the only remaining statistically significant marker of poorer survival after tumor stage. This data confirms a conclusion that has already been well demonstrated by numerous others that have shown both substantial levels of tumor specific SFRP1 hypermethylation in RCC [16,39–41] and that this methylation associates with higher grade and stage in tumors and predicts for poor prognosis in RCC patients [16,40]. SFRP1 protein acts as a WNT antagonist, and thus a tumor suppressor, by inhibiting the activation of the WNT pathway, which when activated can influence cell proliferation, survival and invasion by the canonical/β-catenin pathway and cell adhesion, migration and cytoskeletal reorganization by the non-canonical pathway [42]. Dysregulation of the WNT pathway is a common event in a variety of cancers and this can result from the loss of WNT antagonists like SFRP1, its family members SFRP2-5 and the Wnt inhibitory factor 1 (WIF1) gene or by loss of the Dickkopf genes (DKK1-4) that bind the low-density lipoprotein receptor-related protein 5/6 component of the Wnt receptor complex (Figure S7 in File S1) [42]. Previous publications have demonstrated hypermethylation of many of these genes in RCC [16,39–41,43–47] and within the TCGA data the SFRP2, WIF1, DKK1 and DKK2 genes all had probes that demonstrated hypermethylation in greater than 15% of samples in one cohort. Additionally, before correction for multiple analyses
hypermethylation of \(sfrp1\) associated with poorer survival in both cohorts and hypermethylation of \(sfrp2\) and \(dke2\) associated with poorer survival in a single cohort (Figure S7 in File S1). In combination with the statistically significant association of hypermethylation of \(sfrp1\) with poorer patient survival, this suggests that the dysregulation of the WNT pathway is important for CCRCC tumor progression. Furthermore, although there is a very low rate of somatic mutation for \(sfrp1\) alone, 2.1% of the TCGA CCRCC tumors demonstrated mutually exclusive somatic mutation of regulators of the WNT pathway and this 2.1% had a statistically significantly \((p = 0.017)\) worse rate of survival (Figure S8 in File S1). Thus, this data confirms the importance of hypermethylation of \(sfrp1\) and dysregulation of the WNT pathway in CCRCC and its relevance to poor patient survival. This may well have implications into therapy as a recent paper investigating the effects of both the demethylating drug decitabine (5-aza2'-deoxycytidine) and introduction of recombinant SFRP1 protein on renal and breast cancer lines demonstrated inhibition of cell growth and induction of apoptosis with both treatments [49].

In conclusion, the wealth and breadth of data provided by the Cancer Genome Atlas programs are immense and provide an invaluable tool to researchers in many fields to both confirm and expand upon previous observations, as demonstrated herein, in a large data set or to use as an investigative tool to produce new hypotheses for testing. By just using a fraction of the data, we hope to have provided convincing affirmation for four strong epigenetic markers of CCRCC, two of which may provide essential data for predicting poor patient survival and thus alter therapy. This may become particularly useful as the Illumina BeadChip array analysis can be tailored to produce a specific set of probes, including newly designed ones, to assess specific genes and can be performed using very small amounts of material, such as that provided by a biopsy. The use of demethylating drugs has already proved successful with hematological malignancies and hopefully advances in these therapies will improve their effectiveness in common solid tumors such as clear cell renal cell carcinoma.

Supporting Information

File S1 Includes Figures S1-S8 and Tables S1-S9. Figure S1: Gene Map of the CpG Island for the \(Rncl\) gene demonstrating the Positioning of Probes and the Levels of Hypermethylation. Figure S2: The hypermethylated genes present in either both cohorts or just the HumanMethylation27 or 450 BeadChip cohort only. Figure S3: TCGA KIRC hypermethylated genes that occur in regions of common whole/

References

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 301–309.
2. Howlader N, Noone AM, Krapcho M, Gurney J, Murray T, et al. SEER Cancer Statistics Review, 1975–2015, 2017, posted to the SEER web site, April 2017.
3. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 3: 2169–2173.
4. Latif F, Totty K, Gnarra JR, Yao M, Duh F-M, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–1320.
5. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al. (1994) Silencing of the \(sfrp1\) and \(sfrp2\) genes in renal cancer cell lines by DNA methylation. Proc Natl Acad Sci U S A 91: 9700–9704.
6. The Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43–49.
7. Varella I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene \(pbrm1\) in renal carcinoma. Nature 469: 539–542.
8. Guo G, Gui Y, Gao S, Tang A, Hu X, et al. (2012) Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44: 17–19.
9. Dalgliesh GL, Forre K, Greenman C, Chen I, Bignell G, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360–363.
10. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45: 860–867.
11. Morris MR, Maher ER (2010) Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2: 59.
12. Banks RE, Tiroshida P, Taylor C, Hornigold N, Anusti D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and expression of selected candidate genes in methylated vs unmethylated tumors in the HumanMethylation450 BeadChip cohort. Figure S7: The WNT pathway and the potentially hypermethylated antagonists. Figure S8: Somatic mutation of the WNT pathway regulating genes and its affect on patient survival.

Table S1: The 77 Candidate Hypermethylated Genes for Clear Cell Renal Cell Carcinoma Selected from Published Literature. Table S2: The Methylation Status of the 287 Infinium Probes Representing All 77 Candidate Hypermethylated Genes from the HumanMethylation27 BeadChip Cohort. Table S3: The 182 Hypermethylated Probes from the HumanMethylation450 BeadChip Cohort. Table S4: The Number of Hypermethylated Probes out of all the CpG Island Probes for Each Hypermethylated Gene from the HumanMethylation450 BeadChip Cohort. Table S5: Clinical Information for the HumanMethylation27 BeadChip Cohort and Hypermethylation Status for Significant Genes. Table S6: Clinical Information for the HumanMethylation450 BeadChip Cohort and Hypermethylation Status for Significant Genes. Table S7: Cox Proportional-Hazard Regression Analysis for the Probes that were Statistically Significantly Associated with Poorer Survival in Patients from the HumanMethylation27 BeadChip Cohort compared with Tumor Stage, Tumor Grade, Tumor Maximum Dimension and Patient Gender. Table S8: Kaplan-Meier Survival Curve Analysis for the Single Most Frequently Hypermethylated Probe for each Hypermethylated Gene in the HumanMethylation450 BeadChip Cohort and the Non-Significant Gene Level Results for the HumanMethylation450 BeadChip Cohort. Table S9: Cox Proportional-Hazard Regression Analysis for the Probes or Genes that were Statistically Significantly Associated with Poorer Survival in Patients from the HumanMethylation450 BeadChip Cohort compared with Tumor Stage, Tumor Grade, Tumor Maximum Dimension and Patient Gender.

Author Contributions

Conceived and designed the experiments: CJR VKH WML. Performed the experiments: CJR VKH. Analyzed the data: CJR VKH. Contributed reagents/materials/analysis tools: CJR. Wrote the paper: CJR VKH WML.
15. Hesson LB, Cooper WN, Latif F (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26: 7283–7301.

16. Morris MR, Ricketts C, Gentle D, Abrahamian M, Clarke N, et al. (2010) Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29: 1390–1401.

17. Morris MR, Ricketts C, Gentle D, McDonald R, Carlí N, et al. (2011) Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30: 3295–3304.

18. Hakimi AA, Ostrovnya I, Revá B, Schultz N, Chen YB, et al. (2013) Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21.3: implications in the pathogenesis of renal cell carcinoma. Epigenetics 7: 278–290.

19. Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, et al. (2009) Frequent silencing of sFRP1, a candidate tumor suppressor of breast cancer. Oncogene 28: 4657–4665.

20. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, et al. (2009) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 28: 4676–4684.

21. Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, et al. (2012) FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res 32: 573–584.

22. Hesson LB, Cooper WN, Latif F (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26: 7283–7301.

23. Peters I, Eggers H, Ateşkezeri F, Hennemlotter J, Waalkes S, et al. (2012) GATA3 CpG island methylation in renal cell cancer: a novel biomarker for metastasis and disease progression. BJU Int 110: E144–E152.

24. van Vlodrop IJ, Baldejwinski MM, Smits KM, Schooten LJ, van Neste L, et al. (2010) Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol 176: 575–584.

25. Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, et al. (2005) Aberrant CpG methylation profiling in human non-small cell lung cancer. Lung Cancer 50: 43–49.

26. Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, et al. (2009) PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 125: E11–E17.

27. Urakami S, Shiina H, Enokida H, Hirata K, Kawamoto K, et al. (2006) Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 12: 6989–6997.

28. Hirata H, Nakamura E, Ito N, Kamoto T, Ogawa O (2008) Methyltransferase-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 20: 1257–1263.

29. Kato K, Kanoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042–4045.

30. Hesson LB, Pavlova T, Zabarovska V, Kashuba V, et al. (2009) Hypermethylation affects survival in KIRC patients. PLoS ONE 4: e6767.

31. Haruki S, Iino T, Kozuki K, Matsui T, Kawachi H, et al. (2010) Frequent silencing of proteasome inhibitor 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis 31: 1027–1036.

32. Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, et al. (2012) FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res 32: 4371–4374.

33. Imoto I, Izumi H, Yokoi S, Hossoda H, Shihata T, et al. (2006) Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66: 4617–4626.

34. Shames DS, Girard I, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e186.

35. Shames DS, Girard I, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e186.

36. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, et al. (2009) Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 4: 183–193.

37. Powell R, Coates PJ, Laurell G, Nylander K (2012) p53 Transcriptionally regulates BNC1 , a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer 48: 1401–1406.

38. Dahl E, Wiesmann F, Woensmann M, Stoehr R, Wild PJ, et al. (2007) Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26: 5680–5691.

39. Kawamura Y, Nakamura E, Ito N, Kamoto T, Ogawa O (2008) Methyltransferase-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 20: 1257–1263.

40. Hirata H, Nakamura Y, Nakajima K, Kawamoto K, Kikuno N, et al. (2009) Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 15: 5678–5687.

41. Gmiw ML, Zou H, Kreinert PA, Childs AC, Belmonte LS, et al. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740–4749.

42. Boldrup L, Coates PJ, Laurell G, Nylander K (2012) p53 Transcriptionally regulates BNC1 , a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer 48: 1401–1406.

43. Hesson LB, Pavlova T, Zabarovska V, Kashuba V, et al. (2009) Hypermethylation Affects Survival in KIRC Patients.